Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Artiva Biotherapeutics raised $167 million in its July IPO to advance its innovative cell therapies for autoimmune diseases and cancers. Lead candidate AlloNK, in clinical trials for lupus, is...